ライフサイエンスコーパス: protective immunity

1 inflammation while preserving and enhancing protective immunity.

2 antigen misfolding, hindering generation of protective immunity.

3 tion following vaccination in the absence of protective immunity.

4 been impeded by the absence of correlates of protective immunity.

5 ed by poor understanding of what constitutes protective immunity.

6 , indicating the generation of CT26-specific protective immunity.

7 (+) memory T lymphocytes that participate in protective immunity.

8 n targeting blood-stage parasites results in protective immunity.

9 ant glycoprotein in serum and is crucial for protective immunity.

10 generating IFN-alpha/beta-induced subsequent protective immunity.

11 ) vaccine modalities as a strategy to induce protective immunity.

12 ts that primary Zika virus infection elicits protective immunity.

13 phagocytosis (ADCP) activity, implicated in protective immunity.

14 eptors to detect microorganisms and activate protective immunity.

15 zation strategies are needed to induce cross-protective immunity.

16 nteractions among innate cells that initiate protective immunity.

17 ell response is believed to be important for protective immunity.

18 cating that the vaccines elicited long-lived protective immunity.

19 ed, yet it replicates sufficiently to elicit protective immunity.

20 ar kinetics and induced comparable levels of protective immunity.

21 arameters are often inadequate predictors of protective immunity.

22 atory mechanisms that limit the induction of protective immunity.

23 ecognition receptors (PRRs) is essential for protective immunity.

24 et of these antigens are necessary to elicit protective immunity.

25 e of antigens as a key effector for inducing protective immunity.

26 JENVAC elicits long-lasting, broadly protective immunity.

27 n a single vaccine organism for induction of protective immunity.

28 were not attacked a second time, suggesting protective immunity.

29 an effective NoV vaccine must elicit broadly protective immunity.

30 gnitude, antibodies may act as biomarkers of protective immunity.

31 for potent invasion-inhibitory activity and protective immunity.

32 mulating T cells may provide important cross-protective immunity.

33 n of rhoptries, is also critical in mounting protective immunity.

34 eting distinct epitopes may be necessary for protective immunity.

35 g damaging immunopathology and by inhibiting protective immunity.

36 ed MAIT cells are important for tuberculosis protective immunity.

37 inform ZIKV vaccine strategies for inducing protective immunity.

38 search for malaria antigens associated with protective immunity.

39 the way for better vaccine design to achieve protective immunity.

40 T lymphocytes (CTLs) in heterosubtypic cross-protective immunity.

41 CD8(+) T cells capable of mediating durable protective immunity.

42 in peripheral tissues have distinct roles in protective immunity.

43 ical for systemic, but not mucosal, T. cruzi protective immunity.

44 this subset to improve the effectiveness of protective immunity.

45 CD8(+) T cells are an essential component of protective immunity.

46 idly protected macaques completely abrogated protective immunity.

47 mately 7 days before they are able to elicit protective immunity.

48 tabolism to persist in tissue and to mediate protective immunity.

49 esponse associated with parasite killing and protective immunity.

50 mpartment may provide organisms with broader protective immunity.

51 and that antineuraminidase antibodies offer protective immunity.

52 ic cellular and humoral responses, including protective immunity.

53 in live-attenuated trachoma vaccine-mediated protective immunity.

54 ccine is the identification of mechanisms of protective immunity.

55 l for DC maturation, which may contribute to protective immunity.

56 ith negligible off-target effects, to induce protective immunity.

57 innate immunity and its poor elicitation of protective immunity.

58 ent of IL-17-dependent, Th cell-transferable protective immunity.

59 tural killer (NK) cells were dispensable for protective immunity.

60 nological memory to vaccines is critical for protective immunity.

61 ow recognized as a syndrome of aberrant host protective immunity.

62 PfCSP-reactive B cells in PfSPZ-CVac-induced protective immunity.

63 leads to T cell dysfunction and compromised protective immunity.

64 or models, including complete responses with protective immunity.

65 may contain important epitopes for inducing protective immunity.

66 of VM cells, including their likely role in protective immunity.

67 but they require about 5 to 7 days to induce protective immunity.

68 nce to virus or viral components, can induce protective immunity.

69 -transfer experiments also revealed that the protective immunity afforded by vaccination with the bat

70 Bats develop strong protective immunity after infection with MARV.

71 xplore the role of TRM cells in local tissue protective immunity after rechallenge and vaccination.

72 t lead to the initiation of CD8 TRM-mediated protective immunity after viral infection are unclear.

73 le generation of long-lived memory cells and protective immunity after viral infection.

74 is system is the first capable of generating protective immunity against a broad spectrum of lethal p

75 erior humoral immune responses and conferred protective immunity against a lethal challenge dose of h

76 verely attenuated in vivo but able to elicit protective immunity against a lethal challenge with wild

77 verely attenuated in vivo but able to elicit protective immunity against a lethal challenge with wild

78 observable toxicity in animals and achieved protective immunity against a lethal influenza challenge

79 nstrate that CD8(+) T cells are required for protective immunity against a naturally occurring murine

80 we evaluated whether alpha-GalCer generates protective immunity against a swine influenza (SI) virus

81 to macaques elicited either solid or partial protective immunity against a virulent ocular challenge.

82 coding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolaviru

83 Protective immunity against Aspergillus depends on a hig

84 orm to gain insights regarding mechanisms of protective immunity against B. mallei and B. pseudomalle

85 gamma receptor I (FcgammaRI) contributes to protective immunity against bacterial infections, but ex

86 To determine the role of neutrophils in protective immunity against C. burnetii infection, the R

87 nstrate an important role for neutrophils in protective immunity against C. burnetii infection.

88 IEC-produced IL-7 was only essential for protective immunity against C. rodentium during the firs

89 This process may impair protective immunity against certain opportunistic infect

90 es have proven attenuated in swine, inducing protective immunity against challenge with homologous pa

91 and the tex mutant was capable of providing protective immunity against challenge with wild-type B.

92 Mechanisms of protective immunity against CHIKV are poorly understood,

93 important implications for the induction of protective immunity against Chlamydia and other infectio

94 To provide protective immunity against circulating primary HIV-1 st

95 ent and cell migration, is essential for the protective immunity against Citrobacter rodentium.

96 challenges to defining immune correlates of protective immunity against DENV in field efficacy studi

97 Persistent parasites play a vital role in protective immunity against disease pathology upon reinf

98 This does not induce broad, cross protective immunity against emergent subtypes.

99 the primary antigenic components involved in protective immunity against encapsulated bacterial patho

100 Mechanisms responsible for protective immunity against epicutaneous Candida infecti

101 y cholesterol-modified p40-siRNA established protective immunity against experimental autoimmune ence

102 Immune homeostasis is a prerequisite to protective immunity against gastrointestinal infections.

103 his study demonstrates that the cross-mucosa protective immunity against genital C. trachomatis infec

104 demonstrate that IL-25 is critical for host protective immunity against H. polygyrus bakeri infectio

105 hil-derived IL-4/IL-13 are critical steps in protective immunity against helminths.

106 unization with PR8-amiR-93NP conferred cross-protective immunity against heterologous influenza virus

107 promising candidates to examine induction of protective immunity against heterologous pathogens.

108 no detectable virus replication, indicating protective immunity against homologous strains.

109 T cells provide protective immunity against infections by differentiatin

110 ls to have a diminished capacity to generate protective immunity against influenza virus.

111 ults suggest that ADCC plays a role in cross-protective immunity against influenza.

112 D8 T cell immunity is considered optimal for protective immunity against intracellular Ags.

113 Protective immunity against intracellular pathogens invo

114 Memory cells are a critical component of protective immunity against invading pathogens, especial

115 le leaving intact the neutrophil function in protective immunity against invading pathogens.

116 dicates that DCs are dispensable as APCs for protective immunity against LCMV infection.

117 evelopment of vaccine-induced Th17 cells and protective immunity against lethal experimental infectio

118 Interestingly, vDeltaK1L conferred protective immunity against lethal VACV challenge.

119 Current understanding of the mechanisms of protective immunity against lung infection has been larg

120 ells, in respiratory mucosal vaccine-induced protective immunity against M. tuberculosis.

121 However, their role in protective immunity against Mtb remains unclear due to t

122 ce that exceed the threshold correlated with protective immunity against multiple strains of Zika vir

123 CD4 T cells are critical for protective immunity against Mycobacterium tuberculosis (

124 Development of host protective immunity against Mycobacterium tuberculosis i

125 In contrast, protective immunity against nonfatal cutaneous leishmani

126 es, induced a strong CD8(+) T cell-dependent protective immunity against ocular herpes infection and

127 TEM cells that were associated with a strong protective immunity against ocular herpes infection and

128 ific CD8(+) TEM cells associated with strong protective immunity against ocular herpesvirus infection

129 ecific CD8(+) T cells associated with strong protective immunity against ocular herpesvirus infection

130 These results suggest that protective immunity against P. falciparum can be achieve

131 CD4 TEMRA cells have been implicated in protective immunity against pathogens such as dengue vir

132 Memory CTLs can provide protective immunity against re-exposure to the same path

133 nfection of ERBs with MARV induces long-term protective immunity against reinfection and indicates th

134 opment and studies into the requirements for protective immunity against S. aureus.

135 ed to better understand the requirements for protective immunity against S. aureus.

136 contribution of Th2 cells and basophils for protective immunity against S. mansoni egg-induced patho

137 e efficacy of these NP adjuvants in inducing protective immunity against simian immunodeficiency viru

138 cination with the batA mutant strain elicits protective immunity against subsequent infection with wi

139 In addition, the protective immunity against the cysts remains largely un

140 Infection confers long-term protective immunity against the infecting serotype, but

141 m infection and plays a critical role in the protective immunity against this intestinal attaching an

142 A DENV vaccine capable of eliciting protective immunity against viruses of existing and emer

143 While first infection confers long-term protective immunity against viruses of the infecting ser

144 a SseB with flagellin substantially enhances protective immunity, allowing immunized C57BL/6 mice to

145 robust identification of the true targets of protective immunity ambiguous.

146 The strength of cross-protective immunity among viruses is correlated with the

147 dentify antigenic regions that contribute to protective immunity and are therefore the key targets of

148 mechanism has likely evolved to both sustain protective immunity and avoid autoantibody production.

149 ng the impact of OAS phenotype antibodies on protective immunity and disease severity in secondary in

150 These changes led to decreased protective immunity and enhanced pathology in some mice

151 receptors that regulate the balance between protective immunity and host immune-mediated damage.

152 rus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab ther

153 tion of T cell subsets is important for both protective immunity and immunoregulation.

154 r and describe how macrophages change during protective immunity and inflammation.

155 innate immune system that can contribute to protective immunity and inflammation.

156 e T-cell homeostasis is essential to promote protective immunity and limit autoimmunity and neoplasia

157 er of immunological checkpoints that promote protective immunity and maintain tolerance.

158 as for anthrax, for which rapid induction of protective immunity and memory with a single injection i

159 The unglycosylated G generated high protective immunity and no lung pathology, even in anima

160 s of malaria infection contribute to shaping protective immunity and pathophysiology.

161 ogenes infection inhibited the generation of protective immunity and specifically the activation of a

162 ne aging results in progressive loss of both protective immunity and T cell-mediated suppression, the

163 -modified mRNA-LNP elicits rapid and durable protective immunity and therefore represents a new and p

164 responses need to be controlled for optimal protective immunity and tolerance.

165 sentation, can be targeted in vivo to induce protective immunity, and share characteristics with XCR1

166 he emerging evidence of their importance for protective immunity, and the potential role of resident

167 ogens, we validate that the prime targets of protective immunity are conformational epitopes at the d

168 e difficult partly because the correlates of protective immunity are not fully understood.

169 Although correlates for protective immunity are not yet known, opsonophagocytic

170 al immune functions, including tolerance and protective immunity, are persistently compromised.

171 ll responses.IgE is an important mediator of protective immunity as well as allergic reaction, but ho

172 ed antibody response plays critical roles in protective immunity, as well as in the pathogenesis of a

173 ays, which may not provide a true measure of protective immunity associated with H7 immunization.

174 +)CD127(+)cells that are implicated in early protective immunity at mucosal surfaces.

175 ally delivered vaccines are unable to induce protective immunity at these surfaces.

176 s a pathway for the restoration of long-term protective immunity based on metabolically modified cyto

177 s early sensors of danger signals, mediating protective immunity both through licensing of cellular e

178 Fc receptors on basophils were required for protective immunity but not for regulation of basophil h

179 ously drift, which allows them to circumvent protective immunity, but conserved epitopes provide immu

180 te pathogenic autoimmune cells while sparing protective immunity, but feasible strategies for such an

181 ody response to HPVs is a key determinant of protective immunity, but not all infected individuals se

182 ovirus is an avirulent pathogen that elicits protective immunity, but we discovered that it can nonet

183 focus of vaccine research aimed at inducing protective immunity by antibodies as well as efforts to

184 ne/threonine kinase Akt in the generation of protective immunity by CD8(+) T cells.

185 s vaccine research toward a goal of inducing protective immunity by using WT GP antigens in candidate

186 re, we have pursued a strategy for eliciting protective immunity by vaccinating with small molecules

187 n of pathways related to neutrophil-mediated protective immunity, chemokine/chemokine receptor bindin

188 We propose that the protective immunity conferred by 2D6 IgA is the result o

189 tivity, as well as its multifaceted roles in protective immunity, control of mast cell homeostasis, a

190 ice with a C. neoformans strain that induces protective immunity demonstrated that recruitment of pDC

191 ts in our understanding of the mechanisms of protective immunity, demonstrating a need to measure epi

192 ylococcus aureus infections fail to generate protective immunity despite detectable T and B cell resp

193 lls circumvented the DC defects and provided protective immunity, despite concurrent GVHD.

194 ion by Toxoplasma gondii triggers a lifelong protective immunity due to the persistence of parasitic

195 g antigen presentation and the generation of protective immunity during vaccination or infection.

196 er side of the outer membrane indicates that protective immunity elicited by this antigen cannot be d

197 likely to be associated with differences in protective immunity, especially cross-protection against

198 However, T cells are also critical in protective immunity, especially in immune-compromised pa

199 s against which IgE is an observed marker of protective immunity explains the 'off-target' effects of

200 ctions as a negative regulator to limit host-protective immunity following intradermal infection with

201 hown to induce complete tumor regression and protective immunity following intralesional treatment of

202 epidemiologic settings and demonstration of protective immunity for GII infections provide support f

203 hylococcus aureus does not induce long-lived protective immunity for reasons that are not completely

204 Thus, protective immunity generated during immunization with f

205 f Plasmodium vivax reticulocyte invasion and protective immunity have hampered development of vivax v

206 studies typically examined the biomarkers of protective immunity however the biomarkers of attenuatio

207 lose important epitopes for inducing robust protective immunity.IMPORTANCE The emerging, highly viru

208 dermal model of infection yet still elicited protective immunity.IMPORTANCE The vaccinia virus (VACV)

209 antibody titers were above the threshold for protective immunity in all 78 samples analyzed.

210 ania donovani parasites (LdCen (-/-)) showed protective immunity in animal models.

211 ported to be associated with vaccine-induced protective immunity in challenge studies involving nonhu

212 We also demonstrated maternal protective immunity in challenged newborn mice born to f

213 lower respiratory tract and triggered strong protective immunity in cotton rats.

214 espiratory tract but also triggered a strong protective immunity in cotton rats.

215 gens could lead to a better understanding of protective immunity in human cholera.

216 ponse to the development of population-level protective immunity in humans.

217 S and does not interfere with development of protective immunity in immunized mice.

218 on, thus resulting in the inability to mount protective immunity in immunocompetent hosts.

219 Although ACT has been shown to induce protective immunity in mice, it is not included in any c

220 trains have affected regions responsible for protective immunity in order to decide when new vaccine

221 tosolic multiprotein complexes that initiate protective immunity in response to infection, and can al

222 ed signals are associated with inhibition of protective immunity in susceptible C57BL/6 mice.

223 replication in vivo, may lead to the lack of protective immunity in swine observed after challenge.

224 oreover, by lowering opportunities for cross-protective immunity in the population, conventional vacc

225 help us understand how this vaccine induces protective immunity in this species.

226 ector functions and enhanced vaccine-induced protective immunity in tumor-bearing mice.

227 elanocortin-adenosinergic pathways to induce protective immunity in uveitic patients.

228 coronavirus (SARS-CoV) is a major target of protective immunity in vivo.

229 th mucosal surfaces where they contribute to protective immunity, inappropriate allergic responses, a

230 Since protective immunity induced by IKEPLUS is dependent on a

231 mulation of CD8(+) T cells in the liver, and protective immunity induced by immunization with the Pla

232 enes, the environment, and the microbiome on protective immunity induced by vaccination.

233 ng the high-avidity epitope SSIEFARL induced protective immunity irrespective of gene expression cont

234 with multiple exacerbations, development of protective immunity is critical to improving patient sur

235 Because vaccine-induced protective immunity is critically determined by HIV enve

236 tigation of tractable model systems in which protective immunity is effective has provided a mechanis

237 Thus, host-protective immunity is rarely complete.

238 voring development of auto-inflammation over protective immunity is unclear.

239 Vaccines that induce nonpathogenic protective immunity may soon be available, and it is pos

240 We uncover two inter-organ mechanisms of protective immunity mediated by soluble and cellular fac

241 This chimeric protein elicits protective immunity, mediated by CD4(+) T cells and neut

242 osal delivery would ensure the best onset of protective immunity, most of the candidate vaccines are

243 body dynamics and the natural acquisition of protective immunity over time.

244 juvant properties that improve SseB-mediated protective immunity provided by circulating memory.

245 eople, the mechanisms by which it stimulates protective immunity remain poorly understood.

246 against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV fiel

247 sceptible C57BL/6 mice, but the mechanism of protective immunity remains undefined.

248 Thus, current models of protective immunity require revision.

249 Finally, protective immunity required host expression of IFN-gamm

250 uss the central role of the GI microbiota in protective immunity, resistance to enteric pathogens, an

251 al infection leads to partial but incomplete protective immunity, resulting in subsequent reinfection

252 ass I on CD301b(+) dendritic cells abrogates protective immunity, suggesting the requirement for cogn

253 Chlamydia trachomatis (Ct) infection induces protective immunity that depends on interferon-gamma-pro

254 nd interferon upregulation all contribute to protective immunity that occurs in humans following infl

255 tion in a critical temporal window to impede protective immunity through cytotoxic-T-lymphocyte-assoc

256 1 and Th17 cells have an established role in protective immunity to Bordetella pertussis, but this ev

257 To determine if protective immunity to C. difficile could be generated i

258 n macrophages; however, the role of STAT1 in protective immunity to C. neoformans is unknown.

259 dentity of the specific microbes that elicit protective immunity to different infections is less clea

260 sponses are necessary for the development of protective immunity to helminth parasites but also cause

261 tentially novel correlates and mechanisms of protective immunity to HIV vaccination, thus offering a

262 immune complex composition that may underlie protective immunity to HIV.

263 d to the HA stalk of IBV contribute to cross-protective immunity to IBV of both lineages.

264 ccines have proved ineffective at conferring protective immunity to infants and the elderly, age coho

265 gammadelta T cells play a role in protective immunity to infection at mucosal surface, but

266 e function of Tregs can be the limitation of protective immunity to infectious pathogens.

267 identify key immune epitopes responsible for protective immunity to influenza virus in humans and the

268 cytotoxicity (ADCC) may play a role in cross-protective immunity to influenza virus.

269 xicity [ADCC]-mediating Abs"), may assist in protective immunity to influenza.

270 eeper insight into the real-world dynamic of protective immunity to intestinal pathogens.

271 rasitic infection, and indicate that optimal protective immunity to Leishmania, and thus the success

272 uenza A virus (IAV) and were responsible for protective immunity to lethal challenge with pathogenic

273 her delineate mechanisms whereby HIV impairs protective immunity to M. tuberculosis, we evaluated the

274 Understanding protective immunity to malaria is essential for the desi

275 el strategy for the effective development of protective immunity to malaria.

276 systems, it is unclear which are involved in protective immunity to natural infection in humans.

277 arbohydrate ligand, a potential correlate of protective immunity to NoV infection and illness.

278 designing strategies for the development of protective immunity to pathogens that induce immune resp

279 Naturally acquired protective immunity to Plasmodium falciparum malaria tak

280 Their role in mediating protective immunity to respiratory pathogens, although s

281 la virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EB

282 IL-10 deficiency in mice restores protective immunity to S. aureus infection, and adjuvanc

283 mimics human infection, we show that lack of protective immunity to S. aureus systemic reinfection is

284 Treatment with mAb to IL-10 restored protective immunity to the mutant mice.

285 rcome a defect of CD4(+) T cells in inducing protective immunity to vaccination with a T-dependent in

286 ional profiles suggest a capacity to mediate protective immunity via antigen non-specific bystander k

287 antibody-dependent mechanisms contribute to protective immunity via distinct targets whose identific

288 Protective immunity was associated with temporal recruit

289 In addition, protective immunity was effectively transferred in circu

290 mutant was tested for its vaccine potential, protective immunity was generated in a vaccine/challenge

291 ry environment that favors the generation of protective immunity, whereas tumors are characterized by

292 gen on MHC-I was essential for bTRM-mediated protective immunity, which involved perforin- and IFN-ga

293 ysts in the host or the presence of lifelong protective immunity, which led us to question this dogma

294 sal immune system must initiate and regulate protective immunity, while balancing this immunity with

295 trial, which demonstrated a rapid waning of protective immunity with time, have underscored the need

296 l tumor-associated stroma (TAS) to configure protective immunity within the tumor microenvironment.

297 pproach both mice and swine exhibited strong protective immunity without incurring any appreciable sk

298 A potent adjuvant that induces strong protective immunity without incurring any significant sk

299 velop vaccines against RSV that will provide protective immunity without the potential for disease en

300 tory syncytial virus (RSV) that will provide protective immunity without the potential for vaccine-as